NZ589733A - Oral administration of peripherally-acting opioid antagonists - Google Patents

Oral administration of peripherally-acting opioid antagonists

Info

Publication number
NZ589733A
NZ589733A NZ589733A NZ58973309A NZ589733A NZ 589733 A NZ589733 A NZ 589733A NZ 589733 A NZ589733 A NZ 589733A NZ 58973309 A NZ58973309 A NZ 58973309A NZ 589733 A NZ589733 A NZ 589733A
Authority
NZ
New Zealand
Prior art keywords
opioid
peripherally
oral administration
medicament
opioid antagonists
Prior art date
Application number
NZ589733A
Other languages
English (en)
Inventor
Kevin J Brodbeck
Alan R Kugler
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of NZ589733A publication Critical patent/NZ589733A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ589733A 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists NZ589733A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (1)

Publication Number Publication Date
NZ589733A true NZ589733A (en) 2012-07-27

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589733A NZ589733A (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Country Status (15)

Country Link
US (1) US20110160239A1 (enExample)
EP (1) EP2300009A1 (enExample)
JP (1) JP2011519930A (enExample)
KR (1) KR20110004425A (enExample)
CN (1) CN102014907A (enExample)
AU (1) AU2009244805B2 (enExample)
BR (1) BRPI0912219A2 (enExample)
CA (1) CA2723685C (enExample)
EA (1) EA201001643A1 (enExample)
IL (1) IL208794A0 (enExample)
MX (1) MX2010011727A (enExample)
MY (1) MY156913A (enExample)
NZ (1) NZ589733A (enExample)
WO (1) WO2009137086A1 (enExample)
ZA (1) ZA201007531B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US8524276B2 (en) * 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
MX2013003587A (es) 2010-09-30 2013-05-31 Nektar Therapeutics Conjugados de naloxol-polietilenglicol cristalinos.
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN106470999B (zh) 2014-04-28 2018-11-13 奥佛麦德公司 叔丁啡二聚体及其在治疗肠胃失调中的应用
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
CZ299726B6 (cs) * 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN101466381B (zh) * 2006-04-21 2012-11-14 尼克塔治疗公司 吗啡酮的立体选择性还原
CN101534827A (zh) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 阿片样物质激动剂和阿片样物质拮抗剂的剂型和联合给药

Also Published As

Publication number Publication date
IL208794A0 (en) 2010-12-30
AU2009244805A1 (en) 2009-11-12
KR20110004425A (ko) 2011-01-13
EP2300009A1 (en) 2011-03-30
JP2011519930A (ja) 2011-07-14
ZA201007531B (en) 2012-03-28
BRPI0912219A2 (pt) 2015-10-06
CA2723685A1 (en) 2009-11-12
CN102014907A (zh) 2011-04-13
MX2010011727A (es) 2010-11-30
WO2009137086A1 (en) 2009-11-12
CA2723685C (en) 2016-09-27
EA201001643A1 (ru) 2011-06-30
AU2009244805B2 (en) 2013-01-10
US20110160239A1 (en) 2011-06-30
MY156913A (en) 2016-04-15

Similar Documents

Publication Publication Date Title
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
PH12013501341A1 (en) Morphinan compounds
UA93543C2 (ru) Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
MY149731A (en) Compounds
WO2012079092A3 (en) Testosterone undecanoate compositions
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
PT2510916T (pt) Composição farmacêutica antisséptica para a higiene oral e o tratamento de doenças bucais de origem microbiana
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MY150599A (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
MY154591A (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
NZ596161A (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 MAY 2016 BY CPA GLOBAL

Effective date: 20130322

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2017 BY CPA GLOBAL

Effective date: 20160330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2018 BY THOMSON REUTERS

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2019 BY THOMSON REUTERS

Effective date: 20180418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2020 BY THOMSON REUTERS

Effective date: 20190417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2021 BY THOMSON REUTERS

Effective date: 20200417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2022 BY THOMSON REUTERS

Effective date: 20210403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2023 BY THOMSON REUTERS

Effective date: 20220402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2024 BY THOMSON REUTERS

Effective date: 20230403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2025 BY THOMSON REUTERS

Effective date: 20240401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2026 BY THOMSON REUTERS

Effective date: 20250402